U.S. markets close in 2 hours 51 minutes
  • S&P 500

    3,630.54
    -88.50 (-2.38%)
     
  • Dow 30

    29,135.03
    -548.71 (-1.85%)
     
  • Nasdaq

    10,688.49
    -363.15 (-3.29%)
     
  • Russell 2000

    1,670.78
    -44.47 (-2.59%)
     
  • Crude Oil

    82.83
    +0.68 (+0.83%)
     
  • Gold

    1,667.30
    -2.70 (-0.16%)
     
  • Silver

    18.68
    -0.19 (-1.03%)
     
  • EUR/USD

    0.9772
    +0.0033 (+0.34%)
     
  • 10-Yr Bond

    3.7680
    +0.0630 (+1.70%)
     
  • GBP/USD

    1.1058
    +0.0173 (+1.59%)
     
  • USD/JPY

    144.5300
    +0.4080 (+0.28%)
     
  • BTC-USD

    19,433.20
    -86.80 (-0.44%)
     
  • CMC Crypto 200

    443.92
    -2.06 (-0.46%)
     
  • FTSE 100

    6,881.59
    -123.80 (-1.77%)
     
  • Nikkei 225

    26,422.05
    +248.07 (+0.95%)
     

GW Pharmaceuticals Is Expected to Turn Profitable in 2020

GW Pharmaceuticals Is Expected to Turn Profitable in 2020

In fiscal 2018, which ended on September 30, GW Pharmaceuticals (GWPH) reported total revenue of $12.74 million, a YoY (year-over-year) rise of 15.75%. Additionally, according to the company’s earnings conference call, it also recognized research and development fee revenue after the termination of its agreement with Otsuka Pharmaceuticals and subsequently reacquired the US rights for Sativex. Wall Street analysts expect GW Pharmaceuticals to report non-GAAP (generally accepted accounting principles) diluted EPS of -$6.26 in fiscal 2019, a YoY rise of 40.69%.